Table 3 Treatment
Patient | Gene mutation | CSF gene mutation before IC | Prior systemic treatment | Systemic treatment during IC | Neurological symptom assessment | MRI | Response determination | iPFS (m) | OS (m) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EGFR L858R | Unknown | Gefitinib, Osimertinib | TC + IM | Improved | Improved | Response | 7.3 | 7.3 | ||||
2 | EGFR L858R | Unknown | Surgery, Icotinib, Almonertinib | Pemetrexed + IP | Stable | Stable | Stable | 4 | 4 | ||||
3 | EGFR L858R | Unknown | Gefitinib, Erlotinib, Osimertinib | Osimertinib + IP + BEV | Stable | Stable | Stable | 2.1 | 2.1 | ||||
4 | EGFR 19Del/T790M | Unknown | Gefitinib, Osimertinib | Osimertinib + IP | Improved | Stable | Stable | 8.5 | 8.5 | ||||
5 | EGFR G719A | Unknown | Erlotinib | TC + IP | Worse | Not review | PD | 2 | 2 | ||||
6 | EGFR 20Ins | Unknown | Osimertinib | TC + IM | Stable | Stable | Stable | 3.5 | 3.5 | ||||
7 | Wild-type | Unknown | Surgery, DP, WBRT | TC + IM + BEV | Improved | Improved | Response | 6.8 | 6.8 | ||||
8 | Wild-type | Unknown | PC + BEV | TC + IM + BEV | Improved | Stable | Stable | 16.6 | 16.6 | ||||
9 | Wild-type | Unknown | PC + BEV | Pemetrexed + IM + BEV | Improved | Stable | Stable | 11.6 | 24.3 | ||||
10 | Wild-type | Unknown | PC + BEV | Pemetrexed + IP + BEV | Stable | Stable | Stable | 6.7 | 12 | ||||
11 | Wild-type | Unknown | PC + Pembrolizumab | Pemetrexed + IP | Worse | Not review | PD | 2 | 2 | ||||
12 | Wild-type | Unknown | PC + BEV | PC + IP + BEV | Improved | Improved | Response | 8.1 | 10.7 | ||||
13 | Wild-type | Unknown | Osimertinib + BEV | Osimertinib + IP + BEV | Improved | Improved | Response | 15.1 | 17.8+ | ||||
14 | EGFR 19Del | Unknown | Gefitinib | Afatinib + IP + BEV | Improved | Stable | Stable | 8.5 | 10.7 | ||||
15 | EGFR L858R | Unknown | Gefitinib | Osimertinib + IM + BEV | Improved | Improved | Response | 10.1 | 10.1 | ||||
16 | EGFR L858R | Unknown | Gefitinib | Osimertinib + IP + BEV | Improved | Improved | Response | 11.4 | 11.4 | ||||
17 | EGFR L858R | EGFR L858R | Gefitinib | Almonertinib + IP + BEV | Improved | Improved | Response | 7 | 7 | ||||
18 | EGFR 19Del | EGFR 19Del, MET amplification | Surgery, Gefitinib | Osimertinib + Savolitinib + IP | Improved | Improved | Response | 22.1+ | 22.1+ | ||||
19 | EGFR 19Del | EGFR 19Del | Surgery, Gefitinib | Osimertinib + IP + BEV | Improved | Stable | Stable | 8 | 9.6 | ||||
20 | EGFR L858R | Unknown | Osimertinib, Pemetrexed + BEV | Osimertinib + IM + BEV | Improved | Improved | Response | 3.6 | 13 | ||||
21 | EGFR 19Del | Unknown | Gefitinib, Osimertinib | Osimertinib + IP + BEV | Stable | Stable | Stable | 14.5+ | 14.5+ | ||||
22 | EGFR L858R | Unknown | Icotinib + BEV | Osimertinib + IP | Improved | Stable | Stable | 6 | 6.5 | ||||
23 | EGFR L858R | Unknown | Osimertinib | Osimertinib + IP | Improved | Improved | Response | 14.7+ | 14.7+ | ||||
24 | EGFR 19Del | EGFR 19Del | Gefitinib, Osimertinib | Osimertinib + IP | Stable | Stable | Stable | 6 | 7.3 | ||||
25 | EGFR L858R | Unknown | Icotinib, Osimertinib | Pemetrexed + IP + BEV | Improved | Improved | Response | 5 | 9.8+ | ||||
26 | EGFR L858R | EGFR L858R | Surgery, Gefitinib, Almonertinib | Almonertinib + IP + BEV | Improved | Stable | Stable | 5 | 6.4 | ||||
27 | Wild-type | Unknown | PC + Sintilimab | Sintilimab + IP + BEV | Improved | Improved | Response | 6.6+ | 6.6+ | ||||
28 | EGFR 19Del | Unknown | Surgery, Gefitinib, Osimertinib | Osimertinib + IP + BEV | Stable | Stable | Stable | 9.2 | 11.9+ | ||||
29 | EGFR 20Ins | EGFR 20Ins | TC + BEV, PC Sintilimab, Anlotinib | Almonertinib + IP | Improved | Stable | Stable | 5.8 | 5.8 | ||||
30 | EGFR L858R | EGFR 19Del | Gefitinib, Osimertinib | Osimertinib + IP | Stable | Stable | Stable | 3.9 | 3.9 | ||||
31 | EGFR L858R | EGFR L858R | Osimertinib | Osimertinib(160 mg/day) + IP | Worse | Not review | PD | 1.7 | 1.7 | ||||
32 | EGFR 19Del | Unknown | PC, Osimertinib | Osimertinib(160 mg/day) + IP + BEV | Improved | Improved | Response | 9.6+ | 9.6+ | ||||
33 | EGFR L858R | Unknown | Gefitinib, Almonertinib + BEV | Almonertinib + IP + BEV | Improved | Stable | Stable | 6.4+ | 6.4+ | ||||
34 | EGFR L858R | Unknown | Gefitinib | Osimertinib + IP | Improved | Stable | Stable | 8.7 | 13.2 | ||||
35 | EGFR 19Del | EGFR 19Del | Surgery, Gefitinib, Osimertinib | Osimertinib + IP + BEV | Improved | Stable | Stable | 7.6+ | 7.6+ | ||||
36 | Wild-type | Unknown | PC | Paclitaxel + BEV + IP | Improved | Stable | Stable | 4.5+ | 4.5+ | ||||
37 | Wild-type | Unknown | No | PC + BEV + IP | Worse | Not review | PD | 4 | 4 | ||||
38 | EGFR 19Del | EGFR 19Del | Almonertinib | Almonertinib + BEV + IP | Improved | Stable | Stable | 4.1+ | 4.1+ | ||||
39 | EGFR L858R | Unknown | Icotinib | Almonertinib + BEV + IP | Improved | Stable | Stable | 4.1+ | 4.1+ | ||||
40 | EGFR L858R | Unknown | Gefitinib, Osimertinib | Pemetrexed + BEV + IP | Stable | Stable | Stable | 4.1+ | 4.1+ | ||||
41 | EGFR L861Q | Unknown | Afatinib, Anlotinib Osimertinib | Osimertinib(160 mg/day) + IP | Improved | Stable | Stable | 5 | 5.9 | ||||